Kudun and Partners successfully advised Inspire IVF Public Company Limited, a leading fertility treatment center, on its initial public offering (IPO) and the listing of its shares on the Market for Alternative Investment (mai). Inspire IVF is Asia’s first fertility treatment center to earn both AACI and ISO:9001 certifications and the world’s second to receive Global Healthcare Accreditation (GHA) for its COVID-19 medical travel program. Additionally, it is certified by Temos International for “Excellent in International Reproductive Care” and holds Diplomatic Council accreditation, making it the first clinic in Thailand and Southeast Asia to achieve this honor.
Kudun and Partners provided strategic guidance on the methods and requirements for Inspire IVF’s IPO, ensuring compliance with regulatory frameworks and facilitating a seamless transition to a publicly listed entity. This milestone enables Inspire IVF to raise capital for its ambitious growth plans, including the expansion of branches both domestically and internationally and the addition of preventative and restorative medical services.
The transaction was led by partners; Kudun Sukhumananda and Thitawan Thanasombatpaisarn, supported by associates; Supajit Koosittiphon, Nichapat Anantaseriwittaya, Napassaporn Trakulroong, and Sirivipa Kittisubun.
